Latest Breaking News On - Myotonic dystrophy - Page 4 : comparemela.com

Design Therapeutics, Inc (NASDAQ:DSGN) Receives $5 67 Consensus Target Price from Analysts

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in […]

Rodneyw lappePiper sandlerCorton capital incGroup plcDesign therapeutics incTower research capitalRoyal bankSg americas securitiesDesign therapeuticsGet free reportDirector rodneyResearch capitalGeneral group plcCorton capitalGet freeFriedreich ataxia

Design Therapeutics, Inc (NASDAQ:DSGN) Given Average Recommendation of Hold by Brokerages

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating. The average 12 month price target among brokerages that have issued a report on […]

United statesDeepa prasadLeerink partnrsPiper sandlerRodneyw lappeDesign therapeutics company profileAmerican international group incKokusai asset management coDesign therapeutics incMitsubishi ufjRoyal bankGroup plcAmerica corpManufacturers life insurance companyDesign therapeuticsGet free report

Reviewing Design Therapeutics (NASDAQ:DSGN) and Novartis (NYSE:NVS)

Reviewing Design Therapeutics (NASDAQ:DSGN) and Novartis (NYSE:NVS)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesAlnylam pharmaceuticalsDesign therapeutics incDesign therapeuticsGet free reportGiven design therapeuticFriedreich ataxiaMyotonic dystrophyDesign therapeutics daily

Design Therapeutics (NASDAQ:DSGN) Given New $4 00 Price Target at Royal Bank of Canada

Design Therapeutics (NASDAQ:DSGN – Free Report) had its price target decreased by Royal Bank of Canada from $7.00 to $4.00 in a report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock. A number of other research firms have also issued reports on DSGN. SVB […]

Nova scotiaRodneyw lappeDeepa prasadPiper sandlerLeerink partnrsRoyal bankAvoro capital advisorsSecurities exchange commissionDesign therapeutics incDesign therapeutics company profileBlackrock incVanguard group incDesign therapeuticsFree reportDirector deepa prasadExchange commission

Design Therapeutics, Inc (NASDAQ:DSGN) Short Interest Up 6 1% in October

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,120,000 shares, an increase of 6.1% from the October 15th total of 2,940,000 shares. Based on an average trading volume of 938,000 shares, the short-interest ratio […]

Piper sandlerDeepa prasadRodneyw lappeLeerink partnrsSg americas securitiesDesign therapeutics incRoyal bankSecurities exchange commissionDesign therapeuticsGet free reportDirector rodneyExchange commissionDirector deepa prasadMontreal canFriedreich ataxiaMyotonic dystrophy